Cogent Biosciences Announces Positive Top-Line Results Achieving Statistical Significance Across All Primary And Key Secondary Endpoints From The SUMMIT Trial Of Bezuclastinib In Patients With Non-Advanced Systemic Mastocytosis

Press/Media

Period7 Jul 2025 → 8 Jul 2025

Media coverage

26

Media coverage